Gracell Biotechnologies Inc. American Depositary Shares
GRCL
GRCL was delisted on the 21st of February, 2024.
33 hedge funds and large institutions have $56.3M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0% more funds holding
Funds holding: 33 → 33 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
20% less capital invested
Capital invested by funds: $70M → $56.3M (-$13.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.93M |
| 2 |
O
OrbiMed
New York
|
+$3.37M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.49M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$1.05M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$498K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CII
Capital International Inc
Los Angeles,
California
|
-$6.77M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.32M |
| 3 |
BlackRock
New York
|
-$881K |
| 4 |
CIS
Capital International Sarl
Los Angeles,
California
|
-$684K |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$232K |
GRCL Hedge Fund Activity: Q1 2023 in Review
33 of the 6,281 institutional investors tracked by Wall St. Rank reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q1 2023, worth a combined $56.3M — down 20% from $70M a quarter earlier.
Fund positioning in GRCL was balanced in Q1 2023: 7 funds opened new positions, 7 closed out, 12 added to existing stakes and 8 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $4.93M. The largest seller was Capital International Inc, exiting entirely with an estimated $6.77M sold.
- 33 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $56.3M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q1 2023, down 20% quarter-over-quarter.
- 7 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q1 2023 and 7 closed out, a net change of 0 holders.
- The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q1 2023 was Sphera Funds Management, an estimated $4.93M added.
- The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q1 2023 was Capital International Inc, an estimated $6.77M sold.
Based on aggregated 13F filings for Q1 2023.